Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Large-eddy simulation, convective instability, and modal causality of coaxial supersonic air–water jets considering a swirl effect.
Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in Lung Transplant Patients
